Pharma firm Lupin today said it has posted growth of 40.18 per cent in net profit at Rs 220.62 crore for the fourth quarter ended March 31, over the same period a year ago.
Total income rose to Rs 1,338.6 crore for the quarter ended March 2010, from Rs 1,069 crore over the same period previous fiscal, Lupin Ltd said in a filing to the Bombay Stock Exchange (BSE).
The company's board of directors has proposed a dividend of Rs 13.50 per equity share of face value of Rs 10 each to the shareholders of the company.
Shares of the drug firm reacted positively to the results and surged nearly five per cent to touch a year-high level of Rs 1,833 on the BSE from previous close.
"Lupin has had a very strong year where we have continued to outperform across business segments and markets," Lupin MD Kamal K Sharma said.
Lupin's Japanese subsidiary Lyowa contributed to 11 per cent of the company's total revenues at Rs 534 crore, registering growth of 21 per cent, the filing added.
For the year ended March 31, Lupin has posted net profit of Rs 681.6 crore, up 35.91 per cent over the year-ago period.
Lupin's South African subsidiary, Pharma Dynamics grew 57 per cent to Rs 132 crore, it said.
Shares of Lupin today closed at Rs 1,820.30 on the BSE, up 4.24 per cent from previous close.
